Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis: An analysis of real-world data

Lucy Wang, Adam Cuker, Rajender Reddy et al. Nov 03, 2025 pp. 4897-4897 10.1182/blood-2025-4897

Abstract Background: Portal vein thrombosis (PVT) affects approximately 14% of cirrhosis patients and is associated with increased morbidity...

Association between comorbid depression and antidepressant adherence with adherence to disease-modifying therapies in patients with sickle cell disease in Texas Medicaid

Blessing I. Okoye, Jamie Barner, Hyeun Ah Kang et al. Nov 03, 2025 pp. 6219-6219 10.1182/blood-2025-6219

Abstract Introduction: Depression is a prevalent mental health condition among patients with sickle cell disease (SCD) and is associated wit...

Dissecting how pulmonary remodeling from cigarette smoke impacts clonal hematopoiesis

Taishi Yonezawa, Alejandra Martell, Phillip Erice et al. Nov 03, 2025 pp. 633-633 10.1182/blood-2025-633

Abstract Certain somatic mutations result in clonal expansion of mutated hematopoietic cells — the phenomenon known as clonal hematopoiesis...

Perceived treatment and clinical trial access barriers in relapsed/refractory (R/R) follicular lymphoma: Findings from a national survey

Carolyn Trachtenbroit, Molly Kisiel, Kimberly Demirhan et al. Nov 03, 2025 pp. 4405-4405 10.1182/blood-2025-4405

Abstract Background: Follicular lymphoma (FL) is a relapsing, incurable B-cell non-Hodgkin lymphoma with increasing treatment complexity in...

Isa-PACE in the treatment of functionally high-risk multiple myeloma: Intermediate results.

Anastasia Semenova, Stanislav Kamyshanov, Bella Khakulova et al. Nov 03, 2025 pp. 7573-7573 10.1182/blood-2025-7573

Abstract Introduction. The VRd regimen with autologous hematopoietic stem-cell transplantation (auto-HSCT) is the standard treatment for new...

A rare case of idiopathic non-cirrhotic portal HTN in a patient with idiopathic thrombocytopenia purpura

Fawad Talat, Rehan Ishaque, Hamza Usman et al. Nov 03, 2025 pp. 6600-6600 10.1182/blood-2025-6600

Abstract Introduction: Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare condition characterized by clinical portal hypertensio...

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine

Flávia Xavier, Fernando de Oliveira, Augusto Alves et al. Nov 03, 2025 pp. 8190-8190 10.1182/blood-2025-8190

Abstract Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acu...

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Jay Spiegel, Juan Alderuccio, Amer Beitinjaneh et al. Nov 03, 2025 pp. 1009-1009 10.1182/blood-2025-1009

Abstract Introduction CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has become a standard of care for patients (pts) with r...

Structural insights of stomatin from native human platelets by cryo-EM coupled with “Build and Retrieve” (BaR) data processing.

Xu Han, Zhemin Zhang, Masaru Miyagi et al. Nov 03, 2025 pp. 1237-1237 10.1182/blood-2025-1237

Abstract Background: Stomatin is an integral membrane protein known for cholesterol binding, membrane stiffening, regulating ion channel act...

MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory disease

Alison Maloney, Gilbert Ansa, Graham Craggs et al. Nov 03, 2025 pp. 320-320 10.1182/blood-2025-320

Abstract Background: MLLT1 and 3 are highly homologous histone reader and scaffolding proteins, with sole known roles as critical regulators...

5-HT prompt TPO mRNA transcription via H3Q5 serotonylation

Liang Li, Mo Yang, En-yu Liang et al. Nov 03, 2025 pp. 6751-6751 10.1182/blood-2025-6751

Abstract Background: 5-HT (serotonin) is considered as a novel cell growth factor. Our previous studies have shown that 5-HT is a pleiotropi...

Erythroblastic sarcoma transformation from chronic myeloid leukaemia: A case report

Nagah Elmusharaf, Mohammed Abdelsalam, Mohammed Alghamdi et al. Nov 03, 2025 pp. 7309-7309 10.1182/blood-2025-7309

Abstract Introduction: Erythroblastic sarcoma (ES) is a rare form of myeloid sarcoma(MS). We report an unusual case of ES transforming from...

Mitochondrial dysfunction as a key factor in the predisposition to 14q32-related myeloid hematological malignancies

Jean Pegliasco, Graciela Rabadan, Elodie Rosa et al. Nov 03, 2025 pp. 3212-3212 10.1182/blood-2025-3212

Abstract Myeloid malignancies, including myeloproliferative neoplasms (MPN), myelodysplastic syndromes, and acute myeloid leukemia (AML), ar...

Clinical and laboratory findings in adults with sickle cell disease which increase risk for severe acute chest syndrome

Jason Lofters, Cassandra Chua, Jessica Moore et al. Nov 03, 2025 pp. 1175-1175 10.1182/blood-2025-1175

Abstract Introduction Acute chest syndrome (ACS), the second most common complication of sickle cell disease (SCD), is c...

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Dickran Kazandjian, Benjamin Diamond, James Hoffman et al. Nov 03, 2025 pp. 248-248 10.1182/blood-2025-248

Abstract Background : Proteosome inhibitor (PI), immunomodulatory drug (IMiD), and anti- CD38-based quadruplet (quad) therapies have revolut...

TDI01 in the treatment of moderate to severe chronic graft-versus-host disease: Updated results from a multicenter, OPEN-label phase IB/II study (An Update)

Xiaojun Huang, Xiao-Dong Mo, Xuejun Zhang et al. Nov 03, 2025 pp. 4229-4229 10.1182/blood-2025-4229

Abstract Introduction:This multicenter, open-label Phase Ib/II study evaluated TDI01 in patients with moderate or severe chronic graft-versu...

Single-arm meta-analysis of melflufen-based regimens in relapsed/refractory multiple myeloma: Efficacy and safety insights from clinical trials

Abdul basit Khan, Fawad Talat, Zauha Fawad Memon et al. Nov 03, 2025 pp. 7568-7568 10.1182/blood-2025-7568

Abstract Introduction: Multiple Myeloma (MM) poses a significant challenge in clinical settings, especially among patients with resistant di...

Donor and recipient age-related differences in immunological reconstitution affect development of chronic graft-versus-host disease

Fumihito Tajima, Nozomi Hamada, Takaya Nishio et al. Nov 03, 2025 pp. 4230-4230 10.1182/blood-2025-4230

Abstract Background: Donor source (p=0.032) and patient age (p=0.015) were associated with onset of chronic graft-versus-host disease (cGVHD...

Haematological toxicities with targeted drugs in tumors: A systematic review and network meta-analysis of randomized controlled trials

Xinpu Han, Yu Zhang, Qiuyue Fan et al. Nov 03, 2025 pp. 6541-6541 10.1182/blood-2025-6541

Abstract Objective: Tumor-targeted drug monotherapy or chemotherapy is becoming increasingly important in cancer treatment, yet the concomit...

First-line ibrutinib + venetoclax shows benefit across genomic subgroups in patients with chronic lymphocytic leukemia (CLL): Results from Phase 2 captivate study and Phase 3 glow study

Leo Cheung, Shiquan Wu, Brendan Hodkinson et al. Nov 03, 2025 pp. 5672-5672 10.1182/blood-2025-5672

Abstract Introduction: Genomic alterations, including IGHV mutation status, are predictive for outcomes on chemoimmunotherapy in CLL. Here w...

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

Laurent Frenzel, Thomas Chalopin, Mohamad Mohty et al. Nov 03, 2025 pp. 8151-8151 10.1182/blood-2025-8151

Abstract Introduction Elranatamab (ELRA) is a humanized, bispecific antibody that targets both B-cell maturation antigen (BCMA) on multiple...

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory (R/R) acute myeloid leukemia (AML)

Jose Tinajero, Dat Ngo, Brian Lee et al. Nov 03, 2025 pp. 1684-1684 10.1182/blood-2025-1684

Abstract Background The addition of venetoclax (ven) to intensive chemotherapy (IC) has shown high remission rates in bo...

A functional CAR-T cell atlas to unravel regulatory mechanisms of CAR-T therapies

Sergio Camara-Peña, Paula Rodriguez Marquez, Nuria Planell et al. Nov 03, 2025 pp. 5889-5889 10.1182/blood-2025-5889

Abstract Introduction: Over the past decade, CAR-T therapies have emerged as a groundbreaking treatment for cancer, showing remarkable effic...

Son maintains innate immune homeostasis in HSCs via splicing and retroelement control

Hanzhi Luo, Mariela Cortés-López, Cyrus Tam et al. Nov 03, 2025 pp. 210-210 10.1182/blood-2025-210

Abstract Hematopoietic stem cells (HSC) maintain blood homeostasis during steady state and stress through a balanced regulation of self-rene...

Characteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis

Guneet Janda, Sameer Parikh, Ruah Alyamany et al. Nov 03, 2025 pp. 1202-1202 10.1182/blood-2025-1202

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening hyperinflammatory syndrome resulting from imm...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page